These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 30039553)

  • 1. Interferon gamma in cancer immunotherapy.
    Ni L; Lu J
    Cancer Med; 2018 Sep; 7(9):4509-4516. PubMed ID: 30039553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics and immunotherapy: The current state of play.
    Dunn J; Rao S
    Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.
    Eichmüller SB; Osen W; Mandelboim O; Seliger B
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment.
    Huang Y; Wang HC; Zhao J; Wu MH; Shih TC
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
    Wilky BA
    Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to cancer immunotherapy.
    Draghi A; Chamberlain CA; Furness A; Donia M
    Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of IFNγ responsiveness in patient-derived xenografts.
    Cardenas JJ; Robles-Oteiza C; Politi K
    Methods Enzymol; 2020; 631():415-427. PubMed ID: 31948560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and future perspectives of T cell immunotherapy in cancer.
    de Aquino MT; Malhotra A; Mishra MK; Shanker A
    Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.
    Castro F; Cardoso AP; Gonçalves RM; Serre K; Oliveira MJ
    Front Immunol; 2018; 9():847. PubMed ID: 29780381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of immune escape in the cancer immune cycle.
    Tang S; Ning Q; Yang L; Mo Z; Tang S
    Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets.
    Reva BA; Omelchenko T; Nair SS; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e9-e16. PubMed ID: 33446324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
    Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
    Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
    Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
    Front Immunol; 2021; 12():652160. PubMed ID: 33859645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
    Cao J; Yan Q
    Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eph Receptors in the Immunosuppressive Tumor Microenvironment.
    Janes PW; Vail ME; Ernst M; Scott AM
    Cancer Res; 2021 Feb; 81(4):801-805. PubMed ID: 33177063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.